NIH Reporter #1R01AG095016-01

NIH Grant for TNF Therapy Research in Prodromal Synucleinopathies

This opportunity from the National Institute on Aging (NIA), part of the National Institutes of Health (NIH), seeks grant applications for a research project on TNF therapy in prodromal synucleinopathies. - Government Buyer: - National Institutes of Health (NIH) - National Institute on Aging (NIA) - OEMs and Vendors: - Adalimumab (anti-TNFα therapy) - Products/Services Requested: - Prospective, randomized, double-blind clinical study - Use of adalimumab as the anti-TNFα therapy - Advanced immunophenotyping - Neuroimaging - Digital health assessments - Unique/Notable Requirements: - Focus on individuals with REM Sleep Behavior Disorder (prodromal synucleinopathy) - Aim to evaluate the impact of anti-TNFα therapy on motor and cognitive symptoms - No specific product part numbers or purchase quantities provided - Estimated grant value is approximately $2.36 million

Description

This NIH grant opportunity involves a prospective, randomized, double-blind study assessing the potential of anti-TNFα (adalimumab) to slow or prevent motor and cognitive symptoms of synucleinopathy in individuals with REM Sleep Behavior Disorder. The project includes advanced immunophenotyping, neuroimaging, and digital health assessments. Funding is provided by the Marcus Foundation and the NIH, with a total award amount of approximately $2.36 million for the fiscal year 2025. The project aims to provide mechanistic insights into the role of the TNF pathway in neurodegenerative disease progression.

View original listing